perioperative medication management
DESCRIPTION
Hospital Medicine Grand Rounds - Review the general principles to determine continuation or discontinuation of medications in the perioperative setting.Discuss evidence and controversies around perioperative medication management. Outline a practical guide for perioperative medication management. Discuss the most commonly used medications as well as the ones with increased controversy.TRANSCRIPT
Perioperative Medication Management
Perioperative Medication Management
Moises Auron MD, FAAP, FACPMoises Auron MD, FAAP, FACP
Staff, Department of Hospital MedicineStaff, Department of Hospital Medicine
DisclaimerDisclaimer
• None
ObjectivesObjectives
• Reviews the general principles to determine continuation or discontinuation of medications in the perioperative setting.
• Discuss evidence and controversies around perioperative medication management.
• Outline a practical guide for perioperative medication management.
• Will discuss the most commonly used medications as well as the ones with increased controversy.
JustificationJustification
• Steady increase in surgical complexity- Increased elderly population
• Lack of formal training in perioperative medicine• Involuntarily stopping of initiating new medications• Federal requirement (Joint Commission on
Accreditation of Healthcare Organizations - JCAHO) - #3: Increase safety in medication management- #8: Medication reconciliation – precise and complete
http://www.jointcommission.org/patientsafety/nationalpatientsafetygoals
Evidence of recommendationsEvidence of recommendations
• There are no randomized studies• Expert consensus• Pharmacology knowledge
- Pharmacokinetics- Therapeutic effect - Interaction with anesthetic agents
• Theoretical considerations (MVI)• Case reports
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
Perioperative ConsultPerioperative Consult
• Complete H/P- Understand perioperative risk
• Pharmacologic history:- Prescription drugs- OTC- Multivitamins - Nutritional supplements/herbs- Alcohol; tobacco; drugs
Clay BJ. J Hosp Med. 2008 Nov-Dec;3(6):465-72.
General PrinciplesGeneral Principles
• Stress response to surgery and hemodynamic consequences of anesthesia:
- ↑ sympathetic tone
- ↑ vasopressin
- ↑ cortisol
- ↑ RAAS
- ↑ local vasodilatory prostaglandins
• ↓ GI absorption
- Changes in splacnic blood flow
- Transmural intestinal edema
- Villous atrophy
- Hypomotility
• Ileus, opioids, anticholinergic agents, electrolyte disturbances
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
Pass SE. Am J Health Syst Pharm. 2004 May 1;61(9):899-912.
General PrinciplesGeneral Principles
• Discontinuation - Rebound effects- Withdrawal- Worsening intraoperative
clinical status
• Continuation- Hemorrhage- Hypoglycemia- Interaction with anesthetics- Postoperative complications
• O.R. 2.7 (95% CI, 1.76–4.04)
Pass SE. Am J Health Syst Pharm. 2004 May 1;61(9):899-912.
Kennedy JM. Br J Clin Pharmacol. 2000 Apr;49(4):353-62.
General PrinciplesGeneral Principles
• Abrupt discontinuation can cause withdrawal:
- SSRI
- Beta-blockers
- Clonidine
- Benzodiazepines
- Statins
- Corticosteroids.
Papadopoulos S. Orthopedics 2006; 29:413-17.
Marik PE. Arch Surg. 2008;143(12):1222-1226.
General PrinciplesGeneral Principles
Arch Intern Med. 2006;166:2525-2531.
General PrinciplesGeneral Principles
• Continue medications with rebound or withdrawal potential
• Discontinue:
- Increase surgical risk
- Non-essential for quality of life
• Use clinical reasoning
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
General PrinciplesGeneral Principles
Geriatric patientGeriatric patient
Muravchick S. Anesthesiol Clin NA. 2000;18:74
Singh A. Current Opinion in Anaesthesiology 2010; 23:449–454
↓ Vascular distensibility
Ventricular hypertrophy
↑ preload sensitivity+
↓ baroreflexes ↓ response to hypovolemia
↓ FEV1
↓ closing capacity
Physiologic shunt
+AtelectasisHypoxemiaPneumonia
Geriatric patientGeriatric patient
Rivera R. Anesthesiology 2009; 110:1176–81.
Geriatric patientGeriatric patient
Morbid obese patientsMorbid obese patients
↑ cardiac output
↑ lean body weight
↑ adipose mass
↑ extracellular volume
Lemmens HJM. Current Opinion in Anaesthesiology 2010, 23:485–491.Janmahasatian S, Clin Pharmacokinet 2005; 44:1051–1065.
Lemmens HJM. Current Opinion in Anaesthesiology 2010, 23:485–491.Janmahasatian S, Clin Pharmacokinet 2005; 44:1051–1065.
Morbid obese patientsMorbid obese patients
Evidence of recommendationsEvidence of recommendations
• There are no randomized studies• Expert consensus• Pharmacology knowledge
- Pharmacokinetics- Therapeutic effect - Interaction with anesthetic agents
• Theoretical considerations (MVI)• Case reports
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
• Continue medications with rebound or withdrawal potential
• Discontinue:
- Increase surgical risk
- Non-essential for quality of life
• Use clinical reasoning
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
General PrinciplesGeneral Principles
Case 1Case 175 y/o man with renal mass. PMH HTN, CAD s/p BMS 3 mo ago. On Atenolol 25 mg/d; Clopidogrel 70 mg/d and ASA 81 mg/d.Scheduled for robotic heminephrectomy. What is your recommendation for perioperative management of antiplatelets?
a) Continue clopidogrel and ASAb) Hold both clopidogrel and ASA on day of surgery c) Stop clopidogrel 5 days before surgery and continue ASAd) Stop both clopidogrel and ASA 7 days before surgerye) Stop ASA 7 days before surgery and continue clopidogrel
ASAASA
• Irreversible cyclooxygenase (COX) inhibition• 7-10 days for platelet regeneration• Perioperative use associated with ↓ CV morbidity• Stop for > 5 days ↑ stroke and ACS risk• Decision of continue vs. hold related to
hemorrhagic risk vs. perioperative CV morbidity.- E.g. Neurosurgery; prostate; etc. - Resume 24h after surgery (ACCP 2008)
Oscarsson A. Br J Anaesth. 2010 Mar;104(3):305-12.
O’Riordan JM. Arch Surg. 2009;144(1):69-76.
2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.
Coronary StentsCoronary Stents
2007 ACC/AHA Perioperative Task Force. Circulation. 2009;120:e169-e276.2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.
Other antiplateletsOther antiplatelets
• Thienopyridines - irreversible inhibition of ADP-induced platelet aggregation
• Discontinue:- Clopidogrel – 5 days - Prasugrel – 7 days- Ticlopidine – 10-14 days
• Resume ASAP.• Continue ASA in patients with stents• Unclear data on perioperative safety of dipyridamole
Cohn S. Perioperative Medicine. Mc Graw Hill. 2007. Pp 36-49. Jaffer A. CCJM. 2009; 76(Suppl 4): S37-S44.
NSAIDSNSAIDS• Reversible inhibition of COX-1 ↓ TXA2 ↓ platelet
adhesion- Nephrotoxicity- ↑ bleeding risk x 1.5-2
• COX-2 (celecoxib) – minimal effect of platelet fx- Nephrotoxicity- Adverse cardiovascular effects- ↓ postoperative opioid requirements
• Non-acetylated NSAIDS (salsalate) –no antiplatelet effect
Straube S. Acta Anaesthesiol Scand. 2005;49:601-613.O’Riordan JM. Arch Surg. 2009;144(1):69-76.
• Suggest to hold them pre-operatively due to both nephrotoxicity and GI bleeding risk.
• Antiplatelet effect depends on its half life
- Platelet function analysis (PFA-100) –in-vitro normalization 24h after stopping ibuprofen.
• Discontinue 3 days before surgery
- Ibuprofen can be used up to 24h before
Goldenberg NA. Ann Intern Med 2005 Apr 5;142(7):506-9.
NSAIDSNSAIDS
2008 ACCP Guidelines2008 ACCP Guidelines
2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.Jaffer A. CCJM. 2009; 76(Suppl 4): S37-S44.
CHADS2 ScoreCHADS2 Score
Snow V. Ann Intern Med 2003; 139:1009–1017.Jaffer A. CCJM. 2009; 76(Suppl 4): S37-S44.
• Bridging to LMWH or UH:
- Moderate-high thromboembolic risk
• Prophylactic dose of LMWH:
- Low thromboembolic risk
2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.
2008 ACCP Guidelines2008 ACCP Guidelines
Anticoagulant BridgingAnticoagulant Bridging
• Half life x 4 = discontinuation time- Warfarin ~ 5 days- Start UH or LMWH 36h after last warfarin dose- Last LMWH dose 24h before surgery- Stop UH 6h before surgery
2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.Levy JH. Anesthesiology 2010; 113(3):726 – 45.
Case 2Case 290 y/o woman with PAD and AFib. Meds: warfarin 5 mg/d; ASA 325 mg/d; diltiazem ER 180 mg/d. Scheduled for cataract surgery.What is your recommendation for perioperative management of warfarin and ASA in cataract surgery?
a) Continue both warfarin and ASAb) Stop ASA 7d prior and warfarin 5 d priorc) Bridge warfarin to LMWHd) Cancel surgery given patient’s agee) Stop warfarin 5 d prior and continue ASA
Continue antiplatelets and anticoagulants in cataract surgery
Continue antiplatelets and anticoagulants in cataract surgery
• Prospective cohort study (N = 19,283) no significant difference in local (hemorrhage) or systemic (TIA, ACS) complications among patients that stopped vs. continued ASA and warfarin.
• Retrospective study (N = 48,862) – Review of national cataract surgery databank – warfarin and clopidogrel use not associated with significant increase of anesthetic or hemorrhagic complications that could jeopardize patient’s vision.
Katz J. Ophthalmology 2003 Sep;110(9):1784-8.Benzimra JD. Eye. 2009;23(1):10-16.
• Continue vitamin K antagonists- Dental procedures – use of local haemostatic
agents (epsilon-aminocaproic acid)• Dental hygiene, uncomplicated extractions,
prosthesis, restaurations, endodontics, periodontal therapy
- Minor dermatologic procedures• Mohs; simple excisions
- Cataract surgery; trabeculectomy- EGD, C-scope w/o biopsy; EUS
2008 ACCP Guidelines on Antithrombotic Therapy. Chest. 2008 Jun;133(6 Suppl):299S-339S.Jaffer A. CCJM. 2009; 76(Suppl 4): S37-S44.
2008 ACCP Guidelines2008 ACCP Guidelines
New anticoagulantsNew anticoagulants
Levy JH. Anesthesiology 2010; 113(3):726 – 45.
Stop x 4 half lives = ~ 2 days
Levy JH. Anesthesiology 2010; 113(3):726 – 45.
New anticoagulantsNew anticoagulants
Case 3Case 3
65 y/o man, hyperlipidemia, HTN, diverticulosis. Meds: rosuvastatin, chlorthalidone. Scheduled for left hemicolectomy in 2 wk. Patient is able to climb 2 flight of stairs. What is your recommendation?
a) Stop chlorthalidone on day of surgeryb) Stop both medications on day of surgeryc) Continue both medicationsd) Start atenolol now – adjust dose to HR ~ 60-70x’
DiureticsDiuretics
• It is recommended to stop on day of surgery
- Hypovolemia
- Electrolyte derangement
• Hypokalemia
• Hyponatremia
• Hypo/Hypercalcemia
• Individualize in patients with CHF
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.
RAAS InhibitorsRAAS Inhibitors
ACEI
ARB
Aldosterone antagonists• Eplerenone, spironolactone
Direct renin blocker• Aliskiren
Inhibition of Ang II vasoconstrictor effect
↓ Aldosterone
↑ Vasodilatory agents(Bradykinin, NO, prostacyclin)
ANESTHESIA
+
Fyhrquist F. J Intern Med. 2008 Sep;264(3):224-36. Comfere T. Anesth Analg. 2005;100:636-644.
↑ post-induction hypotension
↑ vasoconstrictor use (adrenergic agonists, vasopressin)
Venous blood “Pooling”
↓ Cardiac output
RR post-induction hypotension treated with vasopressor agents
Rosenman DJ. J Hosp Med. 2008 Jul;3(4):319-25.
RAAS InhibitorsRAAS Inhibitors
Rosenman DJ. J Hosp Med. 2008 Jul;3(4):319-25.
RR post-op MI
RAAS InhibitorsRAAS Inhibitors
• Retrospective study (1996 - 2008)
• N = 10,023 (3,052 ACE vs. control –propension analysis)
• Preop ACEI postop complications- Mortality (OR: 2.83, 95% CI: 1.03 to 7.8; P = 0.04)- Nephrotoxicity (OR: 1.7, 95% CI: 1.22 to 2.38; P = 0.0002- Atrial fibrillation (OR: 1.33, 95% CI: 1.17 to 1.51; P = 0.0001)- Inotropic use (OR: 1.17, 95% CI: 1.07 to 1.29; P = 0.0001).
• Mortality: 1%. - ACEI : x 2 (1.3% vs. 0.7%; OR: 2.00, 95% CI: 1.17- 3.42; P = 0.013).
J Am Coll Cardiol 2009;54:1778–84.
• Stop ACEI – one dose
• Stop ARB – 24 h
• Aliskiren – half life ~ 24 h ~ 3 days?
• Spironolactone – one dose
• Eplerenone – one dose
Whinney C. CCJM. Nov 2009; 76(Suppl 4): S126-S132.Saber W. CCJM. Mar 2006;73(Suppl 1):S82-7.
RAAS Inhibitors - RecommendationsRAAS Inhibitors - Recommendations
Pathophysiology of perioperative ischemiaPathophysiology of perioperative ischemiaIncreased sympathetic toneIncreased sympathetic tone
Increased cathecolamine releaseIncreased cathecolamine release
Increased cortisol Increased cortisol
↑ ↑ Myocardial VOMyocardial VO22
Inflammatory stateInflammatory state
- TNFTNF
- CRPCRP
- IL-1 and IL-6IL-1 and IL-6
- FFAFFA
↑ ↑ Platelet functionPlatelet function
Endothelial dysfunctionEndothelial dysfunction
• AnesthesiaAnesthesia
• Fluid-shifts, anemiaFluid-shifts, anemia
• PainPain
• Increased metabolic demandsIncreased metabolic demands
++
++
Increased plaque shear stressIncreased plaque shear stress
Plaque rupturePlaque rupture
Tissue ↓OTissue ↓O22
Non – Q MINon – Q MI
Perioperative Betablockers Perioperative Betablockers
Chopra V. JAMA. Feb 10 2010; 303(6): 551-2.
Devereaux PJ, et al. Lancet 2008; 371: 1839 – 47.
CVA Death
1ry Outcome AMI
HR 0.84, 95%CI 0.70–0.99 HR 0.73, 95%CI 0.60–0.89
HR 2.17, 95%CI 1.26–3.74
HR 1.33, 95%CI 1.03-1.74
N = 8351 - Metoprolol 4174- Placebo 4177Primary outcome – composite of CV mortality, non-fatal AMI, non-fatal cardiac arrest
Metoprolol succinate 200 mg/d
Lindenauer PK. N Engl J Med 2005;353: 349-61.
RCRI
Diabetes
CAD
CVA
CHF
CKD (cre > 2); GFR < 30?
Perioperative Betablockers Perioperative Betablockers
• N = 940 vascular surgery patients• Cardiac events at 30 days:
- 1-4 wks - O.R. 0.46, 95% CI: 0.27 to 0.76- > 4 wks - O.R. 0.48, 95% CI: 0.29 to 0.79
• Long term mortality:- 1- 4 wks– H.R. 0.52, 95% CI: 0.21 to 0.67- > 4 wks – H.R. 0.50, 95% CI: 0.25 to 0.71
Flu WJ. J Am Coll Cardiol, 2010; 56:1922-1929,
BetabloqueadoresBetabloqueadoresBetabloqueadoresBetabloqueadores
• Class I - continue in patients actively using it• Class IIa
- Probably recommended in vascular surgery in high risk patients (CAD; positive stress test)
- Reasonable in patients with CAD and > 1 CV risk factor. • Class IIb
- Unknown in the absence of CAD- Unknown in the absence of risk factors
• Class III- Do not use in patients with contraindications. - Dangerous to start high doses without slow up-titration in
naïve patients.
Circulation 2009;120;e169-e276;
Hypolipemic agentsHypolipemic agents• Statins
- Favorable evidence (↓ cardiovascular complications) • DECREASE IV
- Decreased venous thromboembolism- Continue
• Cholestiramine- Decrease absorption of other drugs
• Fibrates and Niacine- Rhabdomyolisis- Do not offer perioperative benefits
2007 ACC/AHA Perioperative Task Force. Circulation. 2009;120:e169-e276.Dunkelgrun M. Ann Surg. 2009;249:921-926.Glynn RJ. N Engl J Med. 2009;360:1851-1861.
Discontinue
Other cardiovascular medicationsOther cardiovascular medications
• Clonidine- Anxiolytic properties- Rebound HTN- Continue.
• α-blockers - BPH- Tamsulosine – discontinue before cataract surgery
• Intraoperative floppy iris syndrome- Discontinue
• Calcium channel blockers
- Continue
• Anti-angina; anti-arrhytmics - Continue Abdel-Aziz S. Curr Opin Ophthalm. 2009; 20:37–41
Wallace AW. Anesthesiology. 2004;101:284-293.Bell CM. JAMA. 2009;301:1991-1996.Wijeysundera DN. Anesth Analg. 2003;97:634-641.
Case 4Case 425 y/o man with DM1, CHF (EF 30%), ESRD. Scheduled for renal transplant. Meds: insulin pump, atorvastatin, carvedilol, lisinopril.How would you manage his insulin preoperatively?
a) Stop pump and convert to long acting insulinb) Continue basal infusion of insulinc) Start iv insulin and glucose (glucose clamp)d) Stop pump and start ISS
Objectives of glycemic controlObjectives of glycemic control
• Avoid hypo- and hyperglycemia
• Maintain stable electrolyte balance
• Prevent ketoacidosis
• Maintain strict glycemic control
- ICU: > 110 mg/dL < 180 mg/dL
- Non-ICU: > 100 mg/dL < 140 mg/dL
Meneghini LF. CCJM. Nov 2009; 76 (Suppl 4): S53-S59
Diabetes Care. Jun 2009; 32(6):1119-1131.
Pre-operative DM managementPre-operative DM management
• Stop OHA in AM of surgery
- Chlorpropamide (~2 days before)
- Metformin continue the previous day
- Thiazolidinediones (pioglitazone)
- GLP-1 agonists (exenatide)
- DPP-4 inhibitors (sitagliptine)
Meneghini LF. CCJM. Nov 2009; 76 (Suppl 4): S53-S59Duncan AI. Anesth Analg. 2007;104:42-50.Salpeter S. Cochrane Database Syst Rev. 2002:CD002967.
• Insulin
- Day before same regime
- Day of surgery:
• Do not use short acting insulin
• Long acting insulin: 50% dose
• Insulin pump continue basal rate
Meneghini LF. CCJM. Nov 2009; 76 (Suppl 4): S53-S59Duncan AI. Anesth Analg. 2007;104:42-50.Salpeter S. Cochrane Database Syst Rev. 2002:CD002967.
Pre-operative DM managementPre-operative DM management
• 70/30 Insulin
- Long acting insulin (NPH): 50%
- 50 u 70% = 35 u Administer 50% ~ 17 u
Meneghini LF. CCJM. Nov 2009; 76 (Suppl 4): S53-S59Duncan AI. Anesth Analg. 2007;104:42-50.Salpeter S. Cochrane Database Syst Rev. 2002:CD002967.
Pre-operative DM managementPre-operative DM management
Case 5Case 580 y/o woman with PMR admitted for cholecystectomy. Meds: Prednisone 5 mg/d.
What is your recommendation for perioperative management of steroids?
a) Continue same dose of prednisone
b) Administer 15 mg of prednisone
c) Stop prednisone on day of surgery
d) Administer hydrocortisone 100 mg i.v. upon induction
• Normal adrenal gland ~ 5.7 mg (15.7 μmol) / m2BSA cortisol- Male 1.80 m; 75 kg produces ~ 30 μmol/d of cortisol
• Oral supplementation in a patient without any endogenous cortisol production x2 endogenous production. - overcome biological availability and the first-pass metabolism of
the liver. • Stress endogenous cortisol ↑ 5-6x
• Rationale for perioperative steroid supplementation:- Exogenous glucocorticosteroids suppress the HPAA- Max. stim. adrenal produces ~ 200–300 mg of cortisol- Pts w/ suppressed HPAA need extreme doses of steroids
Perioperative SteroidsPerioperative Steroids
Perioperative SteroidsPerioperative Steroids
• 2 randomized placebo-controlled studies• Patients on basal steroid dose
Yong SL. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005367.
It is not possible to refute or support perioperative steroid supplementation
Marik PE. Arch Surg. 2008;143(12):1222-1226de Lange DW. Eur J Int Med. 2008; 19: 461–467
Axis suppression Minor surgical stress (hernia)
Moderate surgical stress (articular replacement)
Major surgical stress
(CABG)
No
PDN < 5 mg/dPDN < 5 mg/d
Steroids < 3wkSteroids < 3wk
-ve Cosyntropin-ve Cosyntropin
Daily doseDaily dose
No supplementationNo supplementation
Daily doseDaily dose
No supplementationNo supplementation
Daily doseDaily dose
No supplementationNo supplementation
Documented or suspicion
PDN > 20 mg/d > 3wk
Cushingoid
+ve Cosyntropin
Daily dose
No supplementation
Hydrocortisone
50 mg iv (induction)
25 mg iv q8h x 24h-48h
Hydrocortisone
100 mg iv (induction)
50 mg iv q8h x 24h
25 mg iv q8h x 24-48h
Unknown
PDN 5-10 mg PDN 5-10 mg >> 3wk3wk
Daily doseDaily dose
No supplementationNo supplementation
Cosyntropin +veCosyntropin +ve
Hydrocortisone Hydrocortisone
50 mg iv (induction)50 mg iv (induction)
25 mg iv q8h x 24h-25 mg iv q8h x 24h-48h48h
HydrocortisoneHydrocortisone
100 mg iv (induction)100 mg iv (induction)
50 mg iv q8h x 24h50 mg iv q8h x 24h
25 mg iv q8h x 24-48h25 mg iv q8h x 24-48h
Shaw M. CCJM. 2002;69(1):9-11Schiff RL. Med Clin North Am. 2003 Jan;87(1):175-92. Cohn SL. Perioperative Medicine. McGraw Hill. 2006. Pp 158-163.
Perioperative SteroidsPerioperative Steroids
Case 6Case 670 y/o man with COPD; never intubated. Hospitalized 1 y ago. Meds: salmeterol/fluticasone, tiotropium, albuterol prn, montelukast. He is asymptomatic. Scheduled for THA.
How will you manage his COPD medications in preparation for surgery?
a) Stop inhalers. Administer hydrocortisone i.v.
b) Administer prednisone 60 mg/d starting 48 h before surgery
c) Continue all inhalers
d) Perform PFT’s and adjust inhalers accordingly
e) Stop montelukast and start theophylline
COPD / AsthmaCOPD / Asthma
Yamakage M. J Anesth. 2008; 22:412–428
• Continue:- Bronchodilators- Inhaled steroids- Montelukast
• Optimize symptoms- Antibiotics (thick sputum)- Oral steroids (5 days before)
• Stop theophylline (disrhythmias)
Woods BD. Br J Anaesth 2009; 103 (Suppl. 1): i57–i65.Yamakage M. J Anesth. 2008; 22:412–428Silvanus MT. Anesthesiology 2004; 100: 1052–7
COPD / AsthmaCOPD / Asthma
Case 7Case 750 y/o woman with bipolar disorder and paranoid schizophrenia. Meds: Lithium carbonate, valproic acid, olanzapine and escitalopram.Scheduled for mastectomy secondary to breast cancer.
What are your recommendations for management of psychiatric drugs?a) Stop all of them on day of surgery b) Continue valproic acid and Lithium onlyc) Continue olanzapine and escitalopram onlyd) Stop olanzapinee) Continue all of them
Neuropsychiatric drugsNeuropsychiatric drugs
• SSRI:
- Potential antiplatelet effect
- Abrupt withdrawal symptoms
• Continue in perioperative period.
- In certain procedures (neurosurgery) its discontinuation can be considered – discuss with Psychiatry and stop gradually.
Huyse FJ. Psychosomatics 2006; 47:8–22Weinrieb RM. Expert Opin Drug Saf. 2005;4:337-344.Movig KL. Arch Intern Med. 2003;163:2354-2358.Michelson D. Br J Psychiatry. 2000;176:363-368.
• Tricyclic antidepressants:
- inhibit recapture of norepinephrine and serotonin
• Theoretical risk of disrhythmias
• Abrupt discontinuation cholinergic effect
• Continue in perioperative period.
Huyse FJ. Psychosomatics 2006; 47:8–22Cohn SL. Perioperative Medicine. McGraw Hill. 2006. Pp 36-49.Wolfe RM. Am Fam Physician. 1997;56:455-462.Kroenke K. South Med J. 1998;91:358-364.
Neuropsychiatric drugsNeuropsychiatric drugs
• Benzodiazepines continue
• Antipsychotics continue
- Document ECG (QTc)
• MAOI stop 2 weeks before
- Risk of HTN with sympathetic agents
- Serotoninergic syndrome
- Avoid meperidine, thyramine
- Use direct sympathomimetics (phenylefrine)
Huyse FJ. Psychosomatics 2006; 47:8–22Cohn SL. Perioperative Medicine. McGraw Hill. 2006. Pp 36-49.Noble WH. Can J Anaesth. 1992;39:1061-1066.
Neuropsychiatric drugsNeuropsychiatric drugs
• Lithium continue
- Monitor electrolytes (Nephrogenic Diabetes insipidus)
• Antiepileptics continue
- Monitor selum levels
- Consider i.v. use
• Antiparkinson agents continue
- Abrupt discontinuation Malignant neuroleptic Sx
- Neurology consult
Huyse FJ. Psychosomatics 2006; 47:8–22.Cohn SL. Perioperative Medicine. McGraw Hill. 2006. Pp 36-49.Fujii T. Surg Today. 2009;39(9):807-810. Gálvez-Jiménez N. Neurol Clin. 2004;22(2):367-377.Gray EJ. J Oral Maxillofac Surg. 1996;54:909-912.
Neuropsychiatric drugsNeuropsychiatric drugs
Case 8Case 8
50 y/o woman with glioblastoma multiforme.
Meds: Dexamethasone, Levetiracetam, Ginseng, Garlic Ginkgo-biloba. Scheduled for brain tumor removal in 2 weeks.
What is your recommendation for medication management?
a) Continue all her medications
b) Stop all medications on day of surgery
c) Stop Levetiracetam on day of surgery
d) Stop Ginseng and Ginkgo-biloba on day of surgery
e) Stop now the Garlic, Ginseng y Ginkgo-biloba
Supplements and herbsSupplements and herbs
• Used by 33% of surgical patients
• Its complications include:
- AMI, stroke, hemorrhage
- Potentiating anesthetic agents
- Refractoriness to anesthetic agents
- Pharmacologic interactions
Ang-Lee MK. JAMA. 2001;286:208-216.Kaye AD. Anesthesiology Clin N Am 2004; 22:125–139.Rowe DJ. Aesthetic Surg J 2009;29:150–157.
Ginseng
Hypoglycemia Inhibit platelet aggregation (irreversible) PT-PTT in animals Anticoagulant effect of warfarin
Ephedra (ma huang)
AMI, stroke
Deplete endogenous catecholamine depositsIntraoperative hemodynamic instabilityFatal interaction with MAOIs
Garlic
Inhibit platelet aggregation (irreversible) fibrinolysis hemorrhagic risk
Erratic hypotensive activity
Ginkgo-biloba Inhibit PAF hemorrhage risk
Ang-Lee MK. JAMA. 2001;286:208-216.Kaye AD. Anesthesiology Clin N Am 2004; 22:125–139Rowe DJ. Aesthetic Surg J 2009;29:150–157.
Supplements and herbsSupplements and herbs
Kava kava
Sedation, anxiolysis
Sedative effect of anesthetic agents
Addictive potential suppression
St. John’s WortMultiples pharmacologic interactions P450 induction
Echinacea
Activate cellular immunity
Allergic reactions; immunosuppression
Potentiates barbiturates
Valerian Sedative effect of anesthesia
Suppression; refractoriness to anesthesia
Ang-Lee MK. JAMA. 2001;286:208-216.Kaye AD. Anesthesiology Clin N Am 2004; 22:125–139Rowe DJ. Aesthetic Surg J 2009;29:150–157.
Supplements and herbsSupplements and herbs
• Others: Chamomile – anticoagulant effect
• Other resources:
- www.nccam.nih.gov
- www.fda.gov/consumer
- www.herbmed.org
Kaye AD. Anesthesiology Clin N Am 2004; 22:125–139.Rowe DJ. Aesthetic Surg J 2009;29:150–157.
Supplements and herbsSupplements and herbs
Thank you!Thank you!Thank you!Thank you!